Shares of Lipocine Inc. (NASDAQ:LPCN) have earned a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the company, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy rating.
Analysts have set a 12-month consensus price objective of $18.80 for the company and are expecting that the company will post ($0.31) earnings per share for the current quarter, according to Zacks. Zacks has also given Lipocine an industry rank of 87 out of 265 based on the ratings given to its competitors.
LPCN has been the subject of several recent analyst reports. Roth Capital set a $30.00 target price on Lipocine and gave the company a “buy” rating in a report on Tuesday, December 6th. Canaccord Genuity set a $15.00 target price on Lipocine and gave the company a “buy” rating in a report on Tuesday, December 20th. Finally, HC Wainwright initiated coverage on Lipocine in a report on Monday, October 17th. They issued a “buy” rating and a $25.00 target price for the company.
Shares of Lipocine (NASDAQ:LPCN) traded down 2.35% during trading on Wednesday, hitting $3.33. The stock had a trading volume of 91,894 shares. The stock’s market capitalization is $60.81 million. The stock has a 50 day moving average price of $3.66 and a 200-day moving average price of $3.82. Lipocine has a one year low of $2.51 and a one year high of $12.66.
TRADEMARK VIOLATION WARNING: This piece was reported by Sports Perspectives and is the propert of of Sports Perspectives. If you are accessing this piece on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this piece can be read at https://sportsperspectives.com/2017/01/11/lipocine-inc-lpcn-receives-average-rating-of-strong-buy-from-analysts.html.
Several institutional investors have recently added to or reduced their stakes in LPCN. California State Teachers Retirement System acquired a new position in Lipocine during the second quarter valued at about $106,000. JPMorgan Chase & Co. purchased a new position in shares of Lipocine during the third quarter valued at $935,000. Wells Fargo & Company MN purchased a new position in shares of Lipocine during the third quarter valued at $122,000. Carlson Capital L P raised its position in shares of Lipocine by 88.3% in the second quarter. Carlson Capital L P now owns 510,000 shares of the specialty pharmaceutical company’s stock valued at $1,550,000 after buying an additional 239,170 shares during the period. Finally, State Street Corp raised its position in shares of Lipocine by 1,408.9% in the second quarter. State Street Corp now owns 200,679 shares of the specialty pharmaceutical company’s stock valued at $609,000 after buying an additional 187,379 shares during the period. 45.09% of the stock is owned by institutional investors.
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.